Mesa Labs Announces Changes in The Composition of Its Board of Directors
March 06 2019 - 8:00AM
Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa” or the
“Company”) has announced several changes to the composition of its
Board of Directors (the “Board”).
As previously announced, on January 23, 2019 David B. Perez was
appointed to Mesa’s Board, filling the open position created by the
passing of H. Stuart Campbell in December 2018. On March 6,
2019, we announced that Jennifer S. Alltoft was appointed to Mesa’s
Board and that effective April 4, 2019, Michael T. Brooks will
retire from Mesa’s Board, a position he has held for 20
years.
“I would like to welcome David and Jenny to Mesa’s Board and
thank Mike for his years of dedication to the Company,” said John
Sullivan, Chairman of the Board. “We established a goal for
this fiscal year of increasing our Board’s engagement in strategic
decision-making by bringing on new members with highly relevant
market experience in high growth environments. David and
Jenny are perfect fits, bringing many years of involvement and
knowledge in our most important healthcare markets of medical
devices and pharmaceutical manufacturing. Their insights and
guidance in the years ahead will be instrumental in helping Mesa
execute its strategic growth plans.”
With the transition of several of Mesa’s Board positions,
committee membership has been restructured, as follows:
Audit |
Compensation |
Nominating & Governance |
Evan Guillemin (Chair) |
David Kelly (Chair) |
John Schmieder (Chair) |
John Schmieder |
Evan Guillemin |
Robert Dwyer |
David Perez |
David Perez |
Jennifer Alltoft |
About the Directors
David is due to retire from his current position as CEO of
Terumo BCT on April 1, 2019. In his nearly 20 years at the
helm of Terumo BCT, the company grew annual revenues almost
six-fold, to nearly $1 billion and he guided the company through
multiple changes in name and ownership.
Jenny joins after a 32-year career at Pfizer, Inc., where she
held multiple positions in Research and Development, Sales &
Marketing, Technical Support and General Management. In her
most recent experience, she led Pfizer’s Biosimilars business,
growing global revenues from zero in 2015 to approximately $800
million today.
Mike has been instrumental in helping guide Mesa’s growth
through the years, having served on all of its committees during
his tenure. Mike has seen the Company grow revenues from less
than $10 million in 1998 to nearly $100 million today. The
entire Mesa team is grateful for Mike’s contributions to the
Company.
About Mesa Laboratories, Inc.
Mesa is a global technology innovator committed to solving some
of the most critical quality control challenges in the
pharmaceutical, healthcare, industrial safety, environmental and
food and beverage industries. Mesa offers products and
services through four divisions (Sterilization and Disinfection
Control, Instruments, Cold Chain Monitoring and Cold Chain
Packaging) to help our customers ensure product integrity, increase
patient and worker safety, and improve quality of life throughout
the world.
Forward Looking Statements
This press release may contain information that constitutes
"forward-looking statements." Generally, the words "believe,"
“will”, “estimate,” "expect," "project," “anticipate,” “intend” and
similar expressions identify forward-looking statements, which
generally are not historical in nature. However, the absence of
these words or similar expressions does not mean that a statement
is not forward-looking. All statements that address operating
performance, events or developments that we expect or anticipate
will occur in the future — including statements relating to
revenues growth and statements expressing general views about
future operating results — are forward-looking statements.
Management believes that these forward-looking statements are
reasonable as and when made. However, caution should be taken not
to place undue reliance on any such forward-looking statements
because such statements speak only as of the date when made. We
undertake no obligation to publicly update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise, except as required by law. In addition,
forward-looking statements are subject to certain risks and
uncertainties that could cause actual results to differ materially
from our historical experience and present expectations or
projections. These risks and uncertainties include, but are not
limited to, those described in our Annual Report on Form 10-K for
the year ended March 31, 2018, and those described from time to
time in our subsequent reports filed with the Securities and
Exchange Commission.
CONTACT: Gary Owens.; President and CEO, or John Sakys; CFO,
both of Mesa Laboratories, Inc., +1-303-987-8000
For more information about the Company, please visit its website
at www.mesalabs.com.
Mesa Laboratories (NASDAQ:MLAB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Mesa Laboratories (NASDAQ:MLAB)
Historical Stock Chart
From Apr 2023 to Apr 2024